NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies Into Medical Practice. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009. (Treatment Improvement Protocol (TIP) Series, No. 49.)

Cover of Incorporating Alcohol Pharmacotherapies Into Medical Practice

Incorporating Alcohol Pharmacotherapies Into Medical Practice.

Show details

Appendix A—Bibliography

References

  1. Aithal GP, Thornes H, Dwarakanath AD, Tanner AR. (1998). Measurement of carbohydrate-deficient transferrin (CDT) in a general medical clinic: Is this test useful in assessing alcohol consumption? Alcohol and Alcoholism 33 3 304-309. [PubMed: 9632056]
  2. Alcoholics Anonymous. (1984). The AA member—Medications and other drugs: Report from a group of physicians in AA. New York: Alcoholics Anonymous World Services.
  3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington, DC: Author.
  4. American Society of Addiction Medicine. (2001). Patient placement criteria for the treatment of substance use disorders: ASAM-PPC-2R (2nd revised ed.). Chevy Chase, MD: Author.
  5. Anton RF, Moak DH, Latham PK, Waid LR, Myrick H, Voronin K. et al. (2005). Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence Journal of Clinical Psychopharmacology 25 4 349-357. [PubMed: 16012278]
  6. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM. et al. (2006). Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A randomized clinical trial JAMA 295 17 2003-2017. [PubMed: 16670409]
  7. Anton RF, Oroszi G, O'Malley SS, Couper D, Swift R, Pettinati H. et al. (2008). An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study Archives of General Psychiatry 65 2 135-144. [PMC free article: PMC2666924] [PubMed: 18250251]
  8. Babor, T. F., Higgins-Biddle, J. C., Saunders, J. B., & Monteiro, M. G. (2001). The Alcohol Use Disorders Identification Test: Guidelines for use in primary care (2nd ed.). Geneva, Switzerland: World Health Organization Department of Mental Health and Substance Abuse.
  9. Balldin J, Berglund M, Borg S, Mansson M, Bendsten P, Franck J. et al. (2003). A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence Alcoholism: Clinical and Experimental Research 7 7 1142-1149. [PubMed: 12878920]
  10. Bell H, Tallaksen CM, Try K, Haug E. (1994). Carbohydrate-deficient transferrin and other markers of high alcohol consumption: A study of 502 patients admitted consecutively to a medical department Alcoholism: Clinical and Experimental Research 18 5 1103-1108. [PubMed: 7847591]
  11. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. (1998). Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study Alcoholism: Clinical and Experimental Research 22 3 573-579. [PubMed: 9622434]
  12. Bjornsson E, Nordlinder H, Olsson R. (2006). Clinical characteristics and prognostic markers in disulfiram-induced liver injury Journal of Hepatology 44 791-797. [PubMed: 16487618]
  13. Bohn MJ, Krahn DD, Staehler BA. (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics Alcoholism: Clinical and Experimental Research 19 3 600-606. [PubMed: 7573780]
  14. Bouza C, Magro A, Muñoz A, Amate JM. (2004). Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review Addiction 99 7 811-828. [PubMed: 15200577]
  15. Brewer C, Meyers RJ, Johnsen J. (2000). Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs 14 5 329-341.
  16. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi JS. et al. (2004). Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients Archives of General Psychiatry 61 264-271. [PMC free article: PMC3675448] [PubMed: 14993114]
  17. Center for Substance Abuse Treatment. (1995). The role and current status of patient placement criteria in the treatment of substance use disorders. Treatment Improvement Protocol Series 13. HHS Publication No. (SMA) 00-3403. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  18. Center for Substance Abuse Treatment. (1997). A guide to substance abuse services for primary care physicians. Treatment Improvement Protocol Series 24. HHS Publication No. (SMA) 03-3807. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  19. Center for Substance Abuse Treatment. (1998). Naltrexone and alcoholism treatment. Treatment Improvement Protocol Series 28. HHS Publication No. (SMA) 98-3206. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  20. Center for Substance Abuse Treatment. (1999a). Brief interventions and brief therapies for substance abuse. Treatment Improvement Protocol Series 34. HHS Publication No. (SMA) 99-3353. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  21. Center for Substance Abuse Treatment. (1999b). Enhancing motivation for change in substance abuse treatment. Treatment Improvement Protocol Series 35. HHS Publication No. (SMA) 02-3693. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  22. Center for Substance Abuse Treatment. (2001a). KAP keys for clinicians based on TIP 34: Brief interventions and brief therapies for substance abuse. HHS Publication No. (SMA) 01-3601. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  23. Center for Substance Abuse Treatment. (2001b). KAP keys for clinicians based on TIP 35: Enhancing motivation for change in substance abuse treatment. HHS Publication No. (SMA) 01-3603. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  24. Center for Substance Abuse Treatment. (2001c). Quick guide for clinicians based on TIP 34: Brief interventions and brief therapies for substance abuse. HHS Publication No. (SMA) 01-3600. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  25. Center for Substance Abuse Treatment. (2001d). Quick guide for clinicians based on TIP 35: Enhancing motivation for change in substance abuse treatment. HHS Publication No. (SMA) 01-3602. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  26. Center for Substance Abuse Treatment. (2005). Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol Series 42. HHS Publication No. (SMA) 05-3992. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  27. Center for Substance Abuse Treatment. (2006a). Detoxification and substance abuse treatment. Treatment Improvement Protocol Series 45. HHS Publication No. (SMA) 06-4131. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  28. Center for Substance Abuse Treatment. (2006b). The role of biomarkers in the treatment of alcohol use disorders. Substance Abuse Treatment Advisory, 5(4).
  29. Chandrasekaran R, Sivaprakash B, Chitraleka V. (2001). Five years of alcohol de-addiction services in a tertiary care general hospital Indian Journal of Psychiatry 43 58-60. [PMC free article: PMC2955934] [PubMed: 21407840]
  30. Chick J. (1999). Safety issues concerning the use of disulfiram in treating alcohol dependence Drug Safety 20 5 427-435. [PubMed: 10348093]
  31. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R. et al. (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse Alcohol and Alcoholism 35 6 587-593. [PubMed: 11093966]
  32. Chick J, Lehert P, Landron F. Plinius Maior Society (2003). Does acamprosate improve reduction of drinking as well as aiding abstinence? Journal of Psychopharmacology 17 4 397-402. [PubMed: 14870951]
  33. Conigliaro, J., Delos Reyes, C., Parran, T. V., Jr., & Schulz, J. E. (2003). Principles of screening and early intervention. In A. W. Graham, T. K. Schultz, M. F. Mayo-Smith, R. K. Ries, & B. B. Wilford (Eds.), Principles of addiction medicine (3rd ed., pp. 325–335). Chevy Chase, MD: American Society of Addiction Medicine.
  34. Conigliaro J, Justice AC, Gordon AJ, Bryant K. (2006). Role of alcohol in determining human immunodeficiency virus (HIV)—Relevant outcomes: A conceptual model to guide the implementation of evidence-based interventions into practice Medical Care 44 S1-S6. [PubMed: 16849963]
  35. Crowley WF Jr, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H. et al. (2004). Clinical research in the United States at a crossroads: Proposal for a novel public-private partnership to establish a national clinical research enterprise JAMA 287 1120-1126. [PubMed: 14996782]
  36. Czirr SA, Hubbell CL, Milano WE, Frank JM, Reid LD. (1987). Selected opioids modify intake of sweetened ethanol solution among female rats Alcohol 4 3 157-160. [PubMed: 3036176]
  37. Deas D, May MP, Randall C, Johnson N, Anton R. (2005). Naltrexone treatment of adolescent alcoholics: An open-label pilot study Journal of Child and Adolescent Psychopharmacology 15 5 723-728. [PubMed: 16262589]
  38. Edenberg HJ. (2002). The collaborative study on the genetics of alcoholism: An update Alcohol Research & Health 26 214-218. [PMC free article: PMC6683843] [PubMed: 12875050]
  39. Escobar F, Espi F, Canteras M. (1995). Diagnostic tests for alcoholism in primary health care: Compared efficacy of different instruments Drug and Alcohol Dependence 40 2 151-158. [PubMed: 8745137]
  40. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. (2006). Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centre's experience with pharmacotherapy Alcohol and Alcoholism 4 321-327. [PubMed: 16467406]
  41. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL. et al. (1986). Disulfiram treatment of alcoholism: A Veterans Administration cooperative study JAMA 256 1449-1455. [PubMed: 3528541]
  42. Fuller RK, Gordis E. (2004). Does disulfiram have a role in alcoholism treatment today? Addiction 99 21-24. [PubMed: 14678055]
  43. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL. et al. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial JAMA 293 13 1617-1625. [PubMed: 15811981]
  44. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. (1999). Pharmacological treatment of alcohol dependence JAMA 281 1318-1325. [PubMed: 10208148]
  45. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, O'Toole TP. (2001). Relationships between patient characteristics and unsuccessful substance abuse detoxification Journal of Addictive Diseases 20 2 41-53. [PubMed: 11318396]
  46. Hald J, Jacobsen E. (1948). A drug sensitising the organism to ethyl alcohol Lancet 2 1001-1004. [PubMed: 18103475]
  47. Harwood, H. (2000). Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods, and data. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism. Retrieved July 20, 2006, from http://pubs​.niaaa.nih​.gov/publications/economic-2000 .
  48. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. (2006). Targeted versus daily naltrexone: Secondary analysis of effects on average daily drinking Alcoholism: Clinical and Experimental Research 30 5 860-865. [PubMed: 16634855]
  49. Hoffman, P. L., Morrow, L., Phillips, T. J., & Siggins, G. R. (2000). Neuroadaptation to ethanol at the molecular and cellular levels. In A. Noronha, M. Eckardt, & K. Warren (Eds.), Review of NIAAA's neuroscience and behavioral research portfolio. NIAAA Research Monograph No. 34. NIH Publication No. 00-457, pp. 85–188. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.
  50. Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD. (1986). Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations Alcohol 3 1 39-54. [PubMed: 3964437]
  51. Johnson BA, O'Malley SS, Ciraulo DA, Roacher JD, Chambers RA, Sarid-Segal O. et al. (2003). Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects Journal of Clinical Psychopharmacology 23 3 281-293. [PubMed: 12826990]
  52. Kenna GA, McGeary JE, Swift RM. (2004a). Pharmacology, pharmacogenomics, and the future of alcohol dependence treatment, Part 1 American Journal of Health-System Pharmacy 61 2272-2297. [PubMed: 15552634]
  53. Kenna GA, McGeary JE, Swift RM. (2004b). Pharmacology, pharmacogenomics, and the future of alcohol dependence treatment, Part 2 American Journal of Health-System Pharmacy 61 2380-2388. [PubMed: 15581261]
  54. Kiefer F, Holger J, Tarnaske T, Helwig H, Briken P, Holzbach R. et al. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism Archives of General Psychiatry 60 1 92-99. [PubMed: 12511176]
  55. Kiefer F, Wiedemann K. (2004). Combined therapy: What does acamprosate and naltrexone combination tell us? Alcohol and Alcoholism 39 6 542-547. [PubMed: 15456690]
  56. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C. et al. (2004). Effectiveness of naltrexone in a community treatment program Alcoholism: Clinical and Experimental Research 28 11 1710-1717. [PubMed: 15547458]
  57. Kim SW, Grant JE, Adson DE, Remmel RP. (2001). A preliminary report on possible naltrexone and nonsteroidal analgesic interactions Journal of Clinical Psychopharmacology 21 632-634. [PubMed: 11763022]
  58. Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Rüther E. et al. (2006). Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome Alcoholism: Clinical and Experimental Research 30 86-95. [PubMed: 16433735]
  59. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N. et al. (2003). Targeted naltrexone for early problem drinkers Journal of Clinical Psychopharmacology 23 3 294-304. [PubMed: 12826991]
  60. Kranzler HR, Rosenthal RN. (2003). Dual diagnosis: Alcoholism and co-morbid psychiatric disorders American Journal on Addiction 12 Suppl 1 S26-S40. [PubMed: 14972778]
  61. Kranzler HR, Van Kirk J. (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis Alcoholism: Clinical and Experimental Research 25 1335-1341. [PubMed: 11584154]
  62. Kristenson H. (1995). How to get the best out of Antabuse Alcohol and Alcoholism 30 775-783. [PubMed: 8679019]
  63. Litten RZ, Fertig J, Mattson ME, Egli M. (2005). Development of medications for alcohol use disorders: Recent advances and ongoing challenges Expert Opinion on Emerging Drugs 10 2 323-343. [PubMed: 15934870]
  64. Mann K. (2004). Pharmacotherapy of alcohol dependence: A review of the clinical data CNS Drugs 18 8 485-504. [PubMed: 15182219]
  65. Martin B, Clapp L, Alfers J, Beresford TP. (2004). Adherence to court-ordered disulfiram at fifteen months: A naturalistic study Journal of Substance Abuse Treatment 26 233-236. [PubMed: 15063918]
  66. Martin B, Mangum L, Beresford TP. (2005). Use of court-ordered supervised disulfiram therapy at DVA Medical Centers in the United States American Journal on Addictions 14 208-212. [PubMed: 16019971]
  67. Mason BJ. (2005a). Acamprosate in the treatment of alcohol dependence Expert Opinion on Pharmacotherapy 6 2103-2115. [PubMed: 16197362]
  68. Mason BJ. (2005b). Rationale for combining acamprosate and naltrexone for treating alcohol dependence Journal of Studies on Alcohol, Supplement 15 148-156. [PubMed: 16223066]
  69. Mason BJ, Goodman AM, Chabac S, Lehert P. (2006). Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation Journal of Psychiatric Research 40 383-393. [PubMed: 16546214]
  70. McCaul ME, Petry NM. (2003). The role of psychosocial treatments in pharmacotherapy for alcoholism American Journal on Addictions 12 Suppl 1 S41-S52. [PubMed: 14972779]
  71. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ. (2000). Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects Neuropsychopharmacology 22 5 480-492. [PubMed: 10731623]
  72. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation JAMA 284 13 1689-1695. [PubMed: 11015800]
  73. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP. et al. (2001). Predicting treatment response to naltrexone: The influence of craving and family history American Journal on Addictions 10 3 258-268. [PubMed: 11579624]
  74. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM. et al. (1999). Naltrexone's effect on cue-elicited craving among alcoholics in treatment Alcoholism: Clinical and Experimental Research 23 8 1386-1394. [PubMed: 10470982]
  75. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI. et al. (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes Alcoholism: Clinical and Experimental Research 25 11 1634-1647. [PubMed: 11707638]
  76. Myrick H, Anton R. (2004). Recent advances in the pharmacotherapy of alcoholism Current Psychiatry Reports 6 332-338. [PubMed: 15355755]
  77. National Institute on Alcohol Abuse and Alcoholism. (2004). Medical management treatment manual: A clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence. COMBINE Monograph Series, Vol. 2. Bethesda, MD: Author.
  78. National Institute on Alcohol Abuse and Alcoholism. (2006). Helping patients who drink too much: A clinician's guide. Bethesda, MD: Author.
  79. Niederhofer H, Staffen W. (2003). Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents Drug and Alcohol Review 22 3 295-297. [PubMed: 15385223]
  80. Nuwayser, E. S., DeRoo, D. J., Balskovich, P. D., & Tsuk, A. G. (1990). Sustained release injectable naltrexone microcapsules. NIDA Research Monograph 105 (pp. 532–533). Rockville, MD: National Institute on Drug Abuse. [PubMed: 1908558]
  81. Office of Applied Studies. (2007). Results from the 2006 National Survey on Drug Use and Health: National findings. NSDUH Series H-30. HHS Publication No. (SMA) 06-4194. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  82. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. (2007). Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment Journal of Clinical Psychopharmacology 27 5 507-512. [PubMed: 17873686]
  83. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. (1992). Naltrexone and coping skills therapy for alcohol dependence: A controlled study Archives of General Psychiatry 49 881-887. [PubMed: 1444726]
  84. O'Malley, S. S., & Kosten, T. R. (2006). Pharmacotherapy of addictive disorders. In W. R. Miller & K. M. Carroll (Eds.), Rethinking substance abuse: What the science shows, and what we should do about it (pp. 240–256). New York: Guilford.
  85. O'Malley SS, Krishnan-Sarin S, Farren C, O'Connor PG. (2000). Naltrexone-induced nausea in patients treated for alcohol dependence: Clinical predictors and evidence for opioid-mediated effects Journal of Clinical Psychopharmacology 20 1 69-76. [PubMed: 10653211]
  86. O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J. et al. (2003). Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs. specialty care: A nested sequence of 3 randomized trials Archives of International Medicine 163 14 1695-1704. [PubMed: 12885685]
  87. Oscar-Berman M, Marinkovic K. (2003). Alcoholism and the brain: An overview Alcohol Research & Health 27 125-133. [PMC free article: PMC6668884] [PubMed: 15303622]
  88. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP. (1999). The effects of naltrexone on alcohol and cocaine use in dually addicted patients Journal of Substance Abuse Treatment 16 2 163-167. [PubMed: 10023615]
  89. Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. (2005). Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorder Biological Psychiatry 57 1128-1137. [PubMed: 15866552]
  90. Reid LD, Czirr SA, Bensinger CC, Hubbell CL, Volanth AJ. (1987). Morphine and diprenorphine together potentiate intake of alcoholic beverages Alcohol 4 3 161-168. [PubMed: 3036177]
  91. Reid LD, Delconte JD, Nichols ML, Bilsky EJ, Hubbell CL. (1991). Tests of opioid deficiency hypotheses of alcoholism Alcohol 8 4 247-257. [PubMed: 1651735]
  92. Roozen HG, de Waart R, van der Windt D, van den Brink W, de Jong C, Kerkhof A. (2006). A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence European Neuropsychopharmacology 16 311-323. [PubMed: 16361086]
  93. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Polomo T. (2005). Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol and Alcoholism 40 3 227-233. [PubMed: 15797885]
  94. Schuckit, M. A. (2006). Rehabilitation. In Drug and alcohol abuse: A clinical guide to diagnosis and treatment (6th ed., pp. 334–383). New York: Springer.
  95. Sharon, A. C., & Wise, D. L. (1981). Development of drug delivery systems for use in treatment of narcotic addiction. NIDA Research Monograph 28 (pp. 194–213). Rockville, MD: National Institute on Drug Abuse. [PubMed: 6791005]
  96. Sillanaukee P, Aalto M, Seppa K. (1998). Carbohydrate-deficient transferrin and conventional alcohol markers as indicators for brief intervention among heavy drinkers in primary health care Alcoholism: Clinical and Experimental Research 22 4 892-896. [PubMed: 9660318]
  97. Sorvajarvi K, Blake JE, Israel Y, Niemela O. (1996). Sensitivity and specificity of carbohydrate-deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin: Comparison of two methods Alcoholism: Clinical and Experimental Research 20 3 449-454. [PubMed: 8727236]
  98. Spanagel R, Zieglgansberger W. (1997). Anti-craving compounds for ethanol: New pharmacological tools to study addictive processes Trends in Pharmacological Sciences 18 2 54-59. [PubMed: 9090311]
  99. Thomson Healthcare, Inc. (2006). Physicians' desk reference (60th ed., pp. 1175–1177). Montvale, NJ: Thomson PDR.
  100. Thornquist L, Biros M, Olander R, Sterner S. (2002). Health care utilization of chronic inebriates Academic Emergency Medicine 9 4 300-308. [PubMed: 11927454]
  101. Verheul R, Lehert P, Geerlings PJ, Koeter MW, Van Den Brink W. (2005). Predictors of acamprosate efficacy: Results from a pooled analysis of seven European trials including 1,485 alcohol-dependent patients Psychopharmacology (Berl) 178 23 167-173. [PubMed: 15322728]
  102. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. (1992). Naltrexone in the treatment of alcohol dependence Archives of General Psychiatry 49 876-880. [PubMed: 1345133]
  103. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. (1997). Naltrexone and alcohol dependence: Role of subject compliance Archives of General Psychiatry 54 737-743. [PubMed: 9283509]
  104. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. (1995). Effect of naltrexone on alcohol “high” in alcoholics American Journal of Psychiatry 152 4 613-615. [PubMed: 7694913]
  105. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. (2004). Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the U.S. Preventive Services Task Force Annals of Internal Medicine 140 557-568. [PubMed: 15068985]
  106. Williams SH. (2005). Medications for treating alcohol dependence American Family Physician 72 1775-1780. [PubMed: 16300039]
  107. Wright C IV, Vafier JA, Lake R. (1988). Disulfiram-induced fulminating hepatitis: Guidelines for liver-panel monitoring Journal of Clinical Psychiatry 49 430-434. [PubMed: 3053669]
  108. Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pecoud A. (1995). Screening for excessive alcohol drinking: Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume Archives of Internal Medicine 155 17 1907-1911. [PubMed: 7677558]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (945K)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...